Severe hypercalcemic hyperparathyroidism developing in a patient with hyperaldosteronism and renal resistance to parathyroid hormone
We evaluated an African American woman referred in 1986 at age 33 years because of renal potassium and calcium wasting and chronic hip pain. She presented normotensive, hypokalemic, hypocalcemic, normophosphatemic, and hypercalciuric. Marked hyperparathyroidism was evident. Urinary cyclic adenosine...
Gespeichert in:
Veröffentlicht in: | Journal of bone and mineral research 2013-03, Vol.28 (3), p.700-708 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 708 |
---|---|
container_issue | 3 |
container_start_page | 700 |
container_title | Journal of bone and mineral research |
container_volume | 28 |
creator | Park‐Sigal, Jennifer Don, Burl R Porzig, Anne Recker, Robert Griswold, Virginia Sebastian, Anthony Duh, Quan‐Yang Portale, Anthony A Shoback, Dolores Schambelan, Morris |
description | We evaluated an African American woman referred in 1986 at age 33 years because of renal potassium and calcium wasting and chronic hip pain. She presented normotensive, hypokalemic, hypocalcemic, normophosphatemic, and hypercalciuric. Marked hyperparathyroidism was evident. Urinary cyclic adenosine monophosphate (cAMP) excretion did not increase in response to parathyroid hormone (PTH) infusion, indicating renal resistance to PTH. X‐rays and bone biopsy revealed severe osteitis fibrosa cystica, confirming skeletal responsiveness to PTH. Renal potassium wasting, suppressed plasma renin activity, and elevated plasma and urinary aldosterone levels accompanied her hypokalemia, suggesting primary hyperaldosteronism. Hypokalemia resolved with spironolactone and, when combined with dietary sodium restriction, urinary calcium excretion fell and hypocalcemia improved, in accord with the known positive association between sodium intake and calcium excretion. Calcitriol and oral calcium supplements did not suppress the chronic hyperparathyroidism nor did they reduce aldosterone levels. Over time, hyperparathyroid bone disease progressed with pathologic fractures and persistent pain. In 2004, PTH levels increased further in association with worsening chronic kidney disease. Eventually hypercalcemia and hypertension developed. Localizing studies in 2005 suggested a left inferior parathyroid tumor. After having consistently declined, the patient finally agreed to neck exploration in January 2009. Four hyperplastic parathyroid glands were removed, followed immediately by severe hypocalcemia, attributed to “hungry bone syndrome” and hypoparathyroidism, which required prolonged hospitalization, calcium infusions, and oral calcitriol. Although her bone pain resolved, hyperaldosteronism persisted. © 2013 American Society for Bone and Mineral Research. |
doi_str_mv | 10.1002/jbmr.1791 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1323813829</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2892561451</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4211-13d503c52136527d99ce8eb2cd5f1a87104307097879c47177c39b7f512aded93</originalsourceid><addsrcrecordid>eNqN0U1r3DAQBmBRWpJtmkP_QBD0kh6caCTZko5J6CcphX6cjVaa7WqxJUfyJuy9P7zeOC2lEOhlxMCjF4aXkJfAzoAxfr5Z9vkMlIEnZAE1F5VsNDwlC6a1rJgUcEiel7JhjDV10xyQQy6Yksw0C_LzK95iRrreDZid7Rz2wc3bYLMd17ucgg-lp36CXRpC_EFDpJYOdgwYR3oXxvX8wXY-lRFzintvo6cZo-2mWUIZbXRIx0T_iqXrlPsU8QV5trJdweOH94h8f_vm29X76vrzuw9XF9eVkxygAuFrJlzNQTQ1V94YhxqX3Pl6BVYrmE5lihmllXFSgVJOmKVa1cCtR2_EETmdc4ecbrZYxrYPxWHX2YhpW1oQXGgQmv8H5VobIyXoib76h27SNk-H3ytltGyaelKvZ-VyKiXjqh1y6G3etcDafYvtvsV23-JkTx4St8se_R_5u7YJnM_gLnS4ezyp_Xj56ct95C9NGKjM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1287984665</pqid></control><display><type>article</type><title>Severe hypercalcemic hyperparathyroidism developing in a patient with hyperaldosteronism and renal resistance to parathyroid hormone</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Park‐Sigal, Jennifer ; Don, Burl R ; Porzig, Anne ; Recker, Robert ; Griswold, Virginia ; Sebastian, Anthony ; Duh, Quan‐Yang ; Portale, Anthony A ; Shoback, Dolores ; Schambelan, Morris</creator><creatorcontrib>Park‐Sigal, Jennifer ; Don, Burl R ; Porzig, Anne ; Recker, Robert ; Griswold, Virginia ; Sebastian, Anthony ; Duh, Quan‐Yang ; Portale, Anthony A ; Shoback, Dolores ; Schambelan, Morris</creatorcontrib><description>We evaluated an African American woman referred in 1986 at age 33 years because of renal potassium and calcium wasting and chronic hip pain. She presented normotensive, hypokalemic, hypocalcemic, normophosphatemic, and hypercalciuric. Marked hyperparathyroidism was evident. Urinary cyclic adenosine monophosphate (cAMP) excretion did not increase in response to parathyroid hormone (PTH) infusion, indicating renal resistance to PTH. X‐rays and bone biopsy revealed severe osteitis fibrosa cystica, confirming skeletal responsiveness to PTH. Renal potassium wasting, suppressed plasma renin activity, and elevated plasma and urinary aldosterone levels accompanied her hypokalemia, suggesting primary hyperaldosteronism. Hypokalemia resolved with spironolactone and, when combined with dietary sodium restriction, urinary calcium excretion fell and hypocalcemia improved, in accord with the known positive association between sodium intake and calcium excretion. Calcitriol and oral calcium supplements did not suppress the chronic hyperparathyroidism nor did they reduce aldosterone levels. Over time, hyperparathyroid bone disease progressed with pathologic fractures and persistent pain. In 2004, PTH levels increased further in association with worsening chronic kidney disease. Eventually hypercalcemia and hypertension developed. Localizing studies in 2005 suggested a left inferior parathyroid tumor. After having consistently declined, the patient finally agreed to neck exploration in January 2009. Four hyperplastic parathyroid glands were removed, followed immediately by severe hypocalcemia, attributed to “hungry bone syndrome” and hypoparathyroidism, which required prolonged hospitalization, calcium infusions, and oral calcitriol. Although her bone pain resolved, hyperaldosteronism persisted. © 2013 American Society for Bone and Mineral Research.</description><identifier>ISSN: 0884-0431</identifier><identifier>EISSN: 1523-4681</identifier><identifier>DOI: 10.1002/jbmr.1791</identifier><identifier>PMID: 23074096</identifier><identifier>CODEN: JBMREJ</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Aldosterone ; Biopsy ; Bone ; Calcitriol ; Calcium - metabolism ; Cyclic AMP ; Excretion ; Female ; Fractures ; Hip ; Homeostasis ; Humans ; HYPERALDOSTERONISM ; Hypercalcemia ; Hypercalcemia - complications ; Hypercalcemia - physiopathology ; Hyperparathyroidism ; Hyperparathyroidism - complications ; Hyperparathyroidism - physiopathology ; HYPOCALCEMIA ; Hypokalemia ; Kidney - drug effects ; Kidney - physiopathology ; Osteitis ; OSTEITIS FIBROSA CYSTICA ; Pain ; Parathyroid ; PARATHYROID HORMONE ; Parathyroid Hormone - administration & dosage ; Potassium ; Potassium - metabolism ; PSEUDOHYPOPARATHYROIDISM ; Sodium ; Tumors</subject><ispartof>Journal of bone and mineral research, 2013-03, Vol.28 (3), p.700-708</ispartof><rights>Copyright © 2013 American Society for Bone and Mineral Research</rights><rights>Copyright © 2013 American Society for Bone and Mineral Research.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4211-13d503c52136527d99ce8eb2cd5f1a87104307097879c47177c39b7f512aded93</citedby><cites>FETCH-LOGICAL-c4211-13d503c52136527d99ce8eb2cd5f1a87104307097879c47177c39b7f512aded93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjbmr.1791$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjbmr.1791$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23074096$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Park‐Sigal, Jennifer</creatorcontrib><creatorcontrib>Don, Burl R</creatorcontrib><creatorcontrib>Porzig, Anne</creatorcontrib><creatorcontrib>Recker, Robert</creatorcontrib><creatorcontrib>Griswold, Virginia</creatorcontrib><creatorcontrib>Sebastian, Anthony</creatorcontrib><creatorcontrib>Duh, Quan‐Yang</creatorcontrib><creatorcontrib>Portale, Anthony A</creatorcontrib><creatorcontrib>Shoback, Dolores</creatorcontrib><creatorcontrib>Schambelan, Morris</creatorcontrib><title>Severe hypercalcemic hyperparathyroidism developing in a patient with hyperaldosteronism and renal resistance to parathyroid hormone</title><title>Journal of bone and mineral research</title><addtitle>J Bone Miner Res</addtitle><description>We evaluated an African American woman referred in 1986 at age 33 years because of renal potassium and calcium wasting and chronic hip pain. She presented normotensive, hypokalemic, hypocalcemic, normophosphatemic, and hypercalciuric. Marked hyperparathyroidism was evident. Urinary cyclic adenosine monophosphate (cAMP) excretion did not increase in response to parathyroid hormone (PTH) infusion, indicating renal resistance to PTH. X‐rays and bone biopsy revealed severe osteitis fibrosa cystica, confirming skeletal responsiveness to PTH. Renal potassium wasting, suppressed plasma renin activity, and elevated plasma and urinary aldosterone levels accompanied her hypokalemia, suggesting primary hyperaldosteronism. Hypokalemia resolved with spironolactone and, when combined with dietary sodium restriction, urinary calcium excretion fell and hypocalcemia improved, in accord with the known positive association between sodium intake and calcium excretion. Calcitriol and oral calcium supplements did not suppress the chronic hyperparathyroidism nor did they reduce aldosterone levels. Over time, hyperparathyroid bone disease progressed with pathologic fractures and persistent pain. In 2004, PTH levels increased further in association with worsening chronic kidney disease. Eventually hypercalcemia and hypertension developed. Localizing studies in 2005 suggested a left inferior parathyroid tumor. After having consistently declined, the patient finally agreed to neck exploration in January 2009. Four hyperplastic parathyroid glands were removed, followed immediately by severe hypocalcemia, attributed to “hungry bone syndrome” and hypoparathyroidism, which required prolonged hospitalization, calcium infusions, and oral calcitriol. Although her bone pain resolved, hyperaldosteronism persisted. © 2013 American Society for Bone and Mineral Research.</description><subject>Adult</subject><subject>Aldosterone</subject><subject>Biopsy</subject><subject>Bone</subject><subject>Calcitriol</subject><subject>Calcium - metabolism</subject><subject>Cyclic AMP</subject><subject>Excretion</subject><subject>Female</subject><subject>Fractures</subject><subject>Hip</subject><subject>Homeostasis</subject><subject>Humans</subject><subject>HYPERALDOSTERONISM</subject><subject>Hypercalcemia</subject><subject>Hypercalcemia - complications</subject><subject>Hypercalcemia - physiopathology</subject><subject>Hyperparathyroidism</subject><subject>Hyperparathyroidism - complications</subject><subject>Hyperparathyroidism - physiopathology</subject><subject>HYPOCALCEMIA</subject><subject>Hypokalemia</subject><subject>Kidney - drug effects</subject><subject>Kidney - physiopathology</subject><subject>Osteitis</subject><subject>OSTEITIS FIBROSA CYSTICA</subject><subject>Pain</subject><subject>Parathyroid</subject><subject>PARATHYROID HORMONE</subject><subject>Parathyroid Hormone - administration & dosage</subject><subject>Potassium</subject><subject>Potassium - metabolism</subject><subject>PSEUDOHYPOPARATHYROIDISM</subject><subject>Sodium</subject><subject>Tumors</subject><issn>0884-0431</issn><issn>1523-4681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqN0U1r3DAQBmBRWpJtmkP_QBD0kh6caCTZko5J6CcphX6cjVaa7WqxJUfyJuy9P7zeOC2lEOhlxMCjF4aXkJfAzoAxfr5Z9vkMlIEnZAE1F5VsNDwlC6a1rJgUcEiel7JhjDV10xyQQy6Yksw0C_LzK95iRrreDZid7Rz2wc3bYLMd17ucgg-lp36CXRpC_EFDpJYOdgwYR3oXxvX8wXY-lRFzintvo6cZo-2mWUIZbXRIx0T_iqXrlPsU8QV5trJdweOH94h8f_vm29X76vrzuw9XF9eVkxygAuFrJlzNQTQ1V94YhxqX3Pl6BVYrmE5lihmllXFSgVJOmKVa1cCtR2_EETmdc4ecbrZYxrYPxWHX2YhpW1oQXGgQmv8H5VobIyXoib76h27SNk-H3ytltGyaelKvZ-VyKiXjqh1y6G3etcDafYvtvsV23-JkTx4St8se_R_5u7YJnM_gLnS4ezyp_Xj56ct95C9NGKjM</recordid><startdate>201303</startdate><enddate>201303</enddate><creator>Park‐Sigal, Jennifer</creator><creator>Don, Burl R</creator><creator>Porzig, Anne</creator><creator>Recker, Robert</creator><creator>Griswold, Virginia</creator><creator>Sebastian, Anthony</creator><creator>Duh, Quan‐Yang</creator><creator>Portale, Anthony A</creator><creator>Shoback, Dolores</creator><creator>Schambelan, Morris</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TS</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201303</creationdate><title>Severe hypercalcemic hyperparathyroidism developing in a patient with hyperaldosteronism and renal resistance to parathyroid hormone</title><author>Park‐Sigal, Jennifer ; Don, Burl R ; Porzig, Anne ; Recker, Robert ; Griswold, Virginia ; Sebastian, Anthony ; Duh, Quan‐Yang ; Portale, Anthony A ; Shoback, Dolores ; Schambelan, Morris</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4211-13d503c52136527d99ce8eb2cd5f1a87104307097879c47177c39b7f512aded93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Aldosterone</topic><topic>Biopsy</topic><topic>Bone</topic><topic>Calcitriol</topic><topic>Calcium - metabolism</topic><topic>Cyclic AMP</topic><topic>Excretion</topic><topic>Female</topic><topic>Fractures</topic><topic>Hip</topic><topic>Homeostasis</topic><topic>Humans</topic><topic>HYPERALDOSTERONISM</topic><topic>Hypercalcemia</topic><topic>Hypercalcemia - complications</topic><topic>Hypercalcemia - physiopathology</topic><topic>Hyperparathyroidism</topic><topic>Hyperparathyroidism - complications</topic><topic>Hyperparathyroidism - physiopathology</topic><topic>HYPOCALCEMIA</topic><topic>Hypokalemia</topic><topic>Kidney - drug effects</topic><topic>Kidney - physiopathology</topic><topic>Osteitis</topic><topic>OSTEITIS FIBROSA CYSTICA</topic><topic>Pain</topic><topic>Parathyroid</topic><topic>PARATHYROID HORMONE</topic><topic>Parathyroid Hormone - administration & dosage</topic><topic>Potassium</topic><topic>Potassium - metabolism</topic><topic>PSEUDOHYPOPARATHYROIDISM</topic><topic>Sodium</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Park‐Sigal, Jennifer</creatorcontrib><creatorcontrib>Don, Burl R</creatorcontrib><creatorcontrib>Porzig, Anne</creatorcontrib><creatorcontrib>Recker, Robert</creatorcontrib><creatorcontrib>Griswold, Virginia</creatorcontrib><creatorcontrib>Sebastian, Anthony</creatorcontrib><creatorcontrib>Duh, Quan‐Yang</creatorcontrib><creatorcontrib>Portale, Anthony A</creatorcontrib><creatorcontrib>Shoback, Dolores</creatorcontrib><creatorcontrib>Schambelan, Morris</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Physical Education Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of bone and mineral research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Park‐Sigal, Jennifer</au><au>Don, Burl R</au><au>Porzig, Anne</au><au>Recker, Robert</au><au>Griswold, Virginia</au><au>Sebastian, Anthony</au><au>Duh, Quan‐Yang</au><au>Portale, Anthony A</au><au>Shoback, Dolores</au><au>Schambelan, Morris</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Severe hypercalcemic hyperparathyroidism developing in a patient with hyperaldosteronism and renal resistance to parathyroid hormone</atitle><jtitle>Journal of bone and mineral research</jtitle><addtitle>J Bone Miner Res</addtitle><date>2013-03</date><risdate>2013</risdate><volume>28</volume><issue>3</issue><spage>700</spage><epage>708</epage><pages>700-708</pages><issn>0884-0431</issn><eissn>1523-4681</eissn><coden>JBMREJ</coden><abstract>We evaluated an African American woman referred in 1986 at age 33 years because of renal potassium and calcium wasting and chronic hip pain. She presented normotensive, hypokalemic, hypocalcemic, normophosphatemic, and hypercalciuric. Marked hyperparathyroidism was evident. Urinary cyclic adenosine monophosphate (cAMP) excretion did not increase in response to parathyroid hormone (PTH) infusion, indicating renal resistance to PTH. X‐rays and bone biopsy revealed severe osteitis fibrosa cystica, confirming skeletal responsiveness to PTH. Renal potassium wasting, suppressed plasma renin activity, and elevated plasma and urinary aldosterone levels accompanied her hypokalemia, suggesting primary hyperaldosteronism. Hypokalemia resolved with spironolactone and, when combined with dietary sodium restriction, urinary calcium excretion fell and hypocalcemia improved, in accord with the known positive association between sodium intake and calcium excretion. Calcitriol and oral calcium supplements did not suppress the chronic hyperparathyroidism nor did they reduce aldosterone levels. Over time, hyperparathyroid bone disease progressed with pathologic fractures and persistent pain. In 2004, PTH levels increased further in association with worsening chronic kidney disease. Eventually hypercalcemia and hypertension developed. Localizing studies in 2005 suggested a left inferior parathyroid tumor. After having consistently declined, the patient finally agreed to neck exploration in January 2009. Four hyperplastic parathyroid glands were removed, followed immediately by severe hypocalcemia, attributed to “hungry bone syndrome” and hypoparathyroidism, which required prolonged hospitalization, calcium infusions, and oral calcitriol. Although her bone pain resolved, hyperaldosteronism persisted. © 2013 American Society for Bone and Mineral Research.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>23074096</pmid><doi>10.1002/jbmr.1791</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0884-0431 |
ispartof | Journal of bone and mineral research, 2013-03, Vol.28 (3), p.700-708 |
issn | 0884-0431 1523-4681 |
language | eng |
recordid | cdi_proquest_miscellaneous_1323813829 |
source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
subjects | Adult Aldosterone Biopsy Bone Calcitriol Calcium - metabolism Cyclic AMP Excretion Female Fractures Hip Homeostasis Humans HYPERALDOSTERONISM Hypercalcemia Hypercalcemia - complications Hypercalcemia - physiopathology Hyperparathyroidism Hyperparathyroidism - complications Hyperparathyroidism - physiopathology HYPOCALCEMIA Hypokalemia Kidney - drug effects Kidney - physiopathology Osteitis OSTEITIS FIBROSA CYSTICA Pain Parathyroid PARATHYROID HORMONE Parathyroid Hormone - administration & dosage Potassium Potassium - metabolism PSEUDOHYPOPARATHYROIDISM Sodium Tumors |
title | Severe hypercalcemic hyperparathyroidism developing in a patient with hyperaldosteronism and renal resistance to parathyroid hormone |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T16%3A50%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Severe%20hypercalcemic%20hyperparathyroidism%20developing%20in%20a%20patient%20with%20hyperaldosteronism%20and%20renal%20resistance%20to%20parathyroid%20hormone&rft.jtitle=Journal%20of%20bone%20and%20mineral%20research&rft.au=Park%E2%80%90Sigal,%20Jennifer&rft.date=2013-03&rft.volume=28&rft.issue=3&rft.spage=700&rft.epage=708&rft.pages=700-708&rft.issn=0884-0431&rft.eissn=1523-4681&rft.coden=JBMREJ&rft_id=info:doi/10.1002/jbmr.1791&rft_dat=%3Cproquest_cross%3E2892561451%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1287984665&rft_id=info:pmid/23074096&rfr_iscdi=true |